Stately Bio Secures $12 Million in Seed Funding for Cell Therapy Development
Stately Bio, a promising startup based in Palo Alto, California, has successfully raised $12 million in seed funding. The company specializes in developing innovative cell therapies using a cutting-edge live-cell imaging platform powered by machine learning technology.
The funding round was spearheaded by AIX Ventures, with additional contributions from Dimension Capital, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui Global Investment, BoxOne Ventures, Axial VC, as well as notable individuals such as Jeff Dean (Chief Scientist at Google DeepMind), Jeremy Wertheimer (co-founder of ITA Software), and Tom Berry (co-founder of Carbon Health).
With this new financial injection, Stately Bio aims to expand its platform technology and advance its internal pipeline of stem cell-derived therapeutics.
The Vision and Leadership Behind Stately Bio
Established in 2022 by Frank Li, who serves as the CEO, Stately Bio stands out as a pioneering biotechnology company that focuses on integrating machine learning into regenerative medicine. The company has successfully developed a sophisticated computational platform that enables real-time insights into cell identity, quality, and behavior through live-cell imaging.
Utilizing machine learning algorithms, Stately Bio’s imaging platform can accurately identify and monitor cells in real time without the need for fluorescent tags or genetic modification. This advanced technology allows for the quantification of different cell types, tracking of differentiation progress, protocol optimization, and even prediction of manufacturing outcomes – all while ensuring the cells remain unharmed.
Innovative Applications in Regenerative Medicine
Stately Bio has leveraged its technology platform to enhance the differentiation of stem cells into mature cells with significant therapeutic potential, starting with a groundbreaking liver cell program. Compared to existing methods, Stately Bio’s liver cells have demonstrated remarkable improvements in key liver functions, showing a 3x-10x enhancement in metabolic assays. The company is actively exploring opportunities to expand to other cell types and collaborate with partners to further advance the use of its liver cells in toxicity testing, disease modeling, and therapeutic applications.
For biopharmaceutical companies, the real-time insights provided by Stately Bio’s technology offer faster process development cycles, improved quality control, and enhanced consistency, ultimately ensuring that each production run meets the rigorous standards required for patient care.
Stay tuned for more updates on Stately Bio’s groundbreaking advancements in the field of regenerative medicine.
